


orforglipron GLP-1R

oral non-peptide GLP-1R agonist
Ph. III for obesity + type 2 diabetes

from LLC-PK1 cell HTS + opt

N. Engl. J. Med., June 23, 2023

CHUGAI, SHIZUOKA, JP; ELI LILLY, INDIANAPOLIS, IN




danuglipron GLP-1R

oral GLP-1-RA full agonist
obesity Ph. IIb, 2.5-120 mg QD, T2D Ph. II, 40-200 mg
from sensitized cell HTS of 2.8M cmpds + opt.

Press release, June 26, 2023

PFIZER, CAMBRIDGE, MA




vorasidenib IDH1/2

oral first-in-class dual IDH1/IDH2 inhibitor
efficacy in Ph. III for mIDH grade 2 gliomas, 40 mg QD
from SBDD of prior mIDH inhibitor

N. Engl. J. Med., June 4, 2023

AGIOS, CAMBRIDGE; SERVIER, BOSTON, MA




atrasentan ET_AR

oral ET_A receptor antagonist
Ph. III for IgAN, 0.75 mg QD, Ph. II in Alport Syndrome
ligand-based design from prior ET_AR antagonists

Acquisition announcement, June 12, 2023

ABBOTT LABS / CHINOOK THERAPEUTICS




lirafugratinib FGFR2

oral covalent FGFR2 inhibitor
Ph. II for cholangiocarcinoma
from rational design with MD simulations

Cancer Discov., June 4, 2023

RELAY THERAPEUTICS INC., CAMBRIDGE, MA




FLX475 CCR4

oral CCR4 antagonist
Ph. II for immune oncology, 100 mg QD
from optimization of prior CCR4 ligands

J. Clin. Oncol., June 1, 2023

RAPT THERAPEUTICS, SO. SAN FRANCISCO, CA




PCO371 PTH1R

oral PTH1R agonist
preclinical for parathyroid hormone disorders
functional screen vs. cells expressing hPTH1R1

Nature, June 7, 2023

CHUGAI, SHIZUOKA, JP




GNE-7883 pan-TEAD

pan-TEAD inhibitor
preclinical efficacy in xenograft models
from TEAD3-YAP HTS of >2M cmpds + opt.

Nature, June 5, 2023

GENENTECH, SOUTH SAN FRANCISCO, CA




compound 13 DCAF1 ligand

DCAF1 binder
preclinical, applied to targeted protein degradation

from HTS + optimization

ACS Med. Chem. Lett. June 2, 2023

NOVARTIS, BASEL, CH



CT3 topoisomerase II

irreversible trypanosomal topo. II inhibitor
efficacy in Chagas and sleeping sickness models
from phenotypic screen against trypanosomes

Science, June 29, 2023

NOVARTIS (NITD), EMERYVILLE, CA / SINGAPORE